BioSpace News Archive

The global hyperthermia cancer treatment market size is expected to reach US$ 265 million by 2030 from US$ 160 million in 2020, growing at a CAGR of 5.8% from 2021 to 2030.

MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, announced the appointment of Nathalie Corvaïa, Ph.D., as Chief Scientific Officer.

Starlight Cardiovascular announced that it has closed the first $9.48M in an $11.45M Series A financing, which will be used to progress development of its portfolio of pediatric interventional cardiology devices.

Omega Laboratories (“Omega”), a leading provider of laboratory testing solutions, announced the acquisition of Acumium, a leading technology and software development firm.

NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka ), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai ), announced today that four-year efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO ® (viltolarsen).

Icosavax, Inc. today announced the initiation of a Phase 1 clinical trial of IVX-A12, a combination bivalent RSV and hMPV VLP vaccine candidate, in older adults.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022, before the U.S. financial markets open.

GT Biopharma, Inc. today announced that its 2022 Special Shareholders Meeting has been adjourned to October 10, 2022 at 11 a.m. PST due to lack of quorum for its previously scheduled meeting.

Ampio Pharmaceuticals, Inc. received written notification from NYSE American LLC stating that the staff of NYSE Regulation has determined to commence proceedings to delist the Company’s common stock from the Exchange.

AXIM Biotechnologies, Inc. announced that it has received an initial order of 19,000 point-of-care diagnostic tests and 100 readers targeting ocular surface diseases through its exclusive global commercialization partner Verséa Ophthalmics, LLC, marking the Company’s first large-scale revenue generating order.